Cantor Fitzgerald Weighs in on CVRx FY2026 Earnings

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of CVRx in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of ($1.49) for the year. The consensus estimate for CVRx's current full-year earnings is ($1.91) per share.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.03. CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. The business had revenue of $12.35 million for the quarter, compared to the consensus estimate of $14.68 million.

Other research analysts have also recently issued research reports about the company. Canaccord Genuity Group reduced their target price on CVRx from $23.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, April 8th. JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $7.00 price objective (down from $15.00) on shares of CVRx in a report on Friday, May 9th. Piper Sandler reduced their price objective on CVRx from $20.00 to $12.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. Finally, Lake Street Capital dropped their target price on CVRx from $19.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $14.50.

CVRx Price Performance

Shares of CVRx stock traded down $0.07 on Tuesday, hitting $5.86. 282,241 shares of the company traded hands, compared to its average volume of 326,025. CVRx has a 12-month low of $4.30 and a 12-month high of $18.55. The company has a current ratio of 12.06, a quick ratio of 10.23 and a debt-to-equity ratio of 0.69. The company has a market cap of $152.79 million, a P/E ratio of -2.18 and a beta of 1.30. The firm's 50-day simple moving average is $6.57 and its 200 day simple moving average is $11.31.

Insider Buying and Selling at CVRx

In related news, Director Kirk G. Nielsen purchased 10,966 shares of the firm's stock in a transaction on Thursday, May 15th. The shares were acquired at an average cost of $5.45 per share, with a total value of $59,764.70. Following the purchase, the director now directly owns 1,910,134 shares of the company's stock, valued at approximately $10,410,230.30. This trade represents a 0.58% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders acquired a total of 78,666 shares of company stock worth $411,031 over the last three months. Company insiders own 13.90% of the company's stock.

Institutional Trading of CVRx

A number of institutional investors have recently made changes to their positions in CVRX. Tower Research Capital LLC TRC boosted its position in CVRx by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company's stock valued at $49,000 after buying an additional 1,186 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of CVRx by 4.5% during the 4th quarter. Bank of New York Mellon Corp now owns 30,377 shares of the company's stock valued at $385,000 after buying an additional 1,296 shares in the last quarter. Rhumbline Advisers increased its stake in shares of CVRx by 13.0% during the first quarter. Rhumbline Advisers now owns 19,018 shares of the company's stock valued at $233,000 after purchasing an additional 2,192 shares in the last quarter. Larson Financial Group LLC bought a new position in CVRx during the 1st quarter valued at approximately $28,000. Finally, Barclays PLC raised its position in shares of CVRx by 12.1% in the 4th quarter. Barclays PLC now owns 21,378 shares of the company's stock worth $270,000 after purchasing an additional 2,311 shares during the last quarter. Hedge funds and other institutional investors own 75.27% of the company's stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.